Scarica l'app Stockscreener
4.22
0.47%
-0.02
Dopo l'orario di chiusura:
4.23
0.01
+0.24%
Precedente Chiudi:
$4.24
Aprire:
$4.35
Volume 24 ore:
6.07M
Relative Volume:
0.98
Capitalizzazione di mercato:
$912.27M
Reddito:
$76.20M
Utile/perdita netta:
$-17.37M
Rapporto P/E:
463.74
EPS:
0.0091
Flusso di cassa netto:
$-75.81M
1 W Prestazione:
-4.09%
1M Prestazione:
-26.99%
6M Prestazione:
+48.59%
1 anno Prestazione:
+586.07%
Intervallo 1D:
$4.08
$4.47
Intervallo di 1 settimana:
$4.08
$5.15
Portata 52W:
$0.40
$8.21
Cytomx Therapeutics Inc Stock (CTMX) Company Profile
Nome
Cytomx Therapeutics Inc
Settore
Industria
Telefono
650.515.3185
Indirizzo
151 OYSTER POINT BLVD., SOUTH SAN FRANCISCO, CA
Compare CTMX vs VRTX, REGN, ALNY, ARGX, INSM
| Azioni | Prezzo | Cap. di mercato | Reddito | Reddito netto | Flusso di cassa | EPS |
|---|---|---|---|---|---|---|
CTMX
Cytomx Therapeutics Inc
|
4.22 | 916.59M | 76.20M | -17.37M | -75.81M | 0.0091 |
VRTX
Vertex Pharmaceuticals Inc
|
454.97 | 113.96B | 12.07B | 3.95B | 3.19B | 15.33 |
REGN
Regeneron Pharmaceuticals Inc
|
749.47 | 78.41B | 14.34B | 4.50B | 3.77B | 41.56 |
ALNY
Alnylam Pharmaceuticals Inc
|
328.70 | 40.85B | 3.71B | 313.75M | 465.38M | 2.2571 |
ARGX
Argen X Se Adr
|
697.05 | 42.05B | 4.16B | 1.29B | 734.26M | 19.58 |
INSM
Insmed Inc
|
148.31 | 29.99B | 606.42M | -1.28B | -997.58M | -6.403 |
Cytomx Therapeutics Inc Stock (CTMX) Upgrades & Downgrades
| Data | Azione | Analista | Modifica della valutazione |
|---|---|---|---|
| 2026-03-16 | Aggiornamento | JP Morgan | Neutral → Overweight |
| 2026-01-20 | Iniziato | Guggenheim | Buy |
| 2025-09-22 | Iniziato | Cantor Fitzgerald | Overweight |
| 2025-09-17 | Ripresa | Barclays | Overweight |
| 2025-07-31 | Iniziato | Oppenheimer | Outperform |
| 2025-05-15 | Aggiornamento | H.C. Wainwright | Neutral → Buy |
| 2025-04-14 | Ripresa | Piper Sandler | Overweight |
| 2024-05-28 | Aggiornamento | Piper Sandler | Neutral → Overweight |
| 2024-05-09 | Aggiornamento | Wedbush | Neutral → Outperform |
| 2024-05-06 | Aggiornamento | Jefferies | Hold → Buy |
| 2024-04-22 | Aggiornamento | JP Morgan | Underweight → Neutral |
| 2022-11-14 | Downgrade | BMO Capital Markets | Outperform → Market Perform |
| 2022-07-07 | Downgrade | Jefferies | Buy → Hold |
| 2022-07-07 | Downgrade | Mizuho | Buy → Neutral |
| 2022-07-07 | Downgrade | Piper Sandler | Overweight → Neutral |
| 2022-07-07 | Downgrade | Wedbush | Outperform → Neutral |
| 2022-06-24 | Iniziato | BMO Capital Markets | Outperform |
| 2022-01-18 | Aggiornamento | Barclays | Underweight → Overweight |
| 2021-11-15 | Iniziato | BTIG Research | Buy |
| 2021-05-28 | Downgrade | Barclays | Equal Weight → Underweight |
| 2021-03-29 | Iniziato | JP Morgan | Overweight |
| 2021-03-23 | Aggiornamento | Jefferies | Hold → Buy |
| 2020-09-22 | Downgrade | Guggenheim | Buy → Neutral |
| 2020-06-01 | Downgrade | Jefferies | Buy → Hold |
| 2020-05-14 | Reiterato | H.C. Wainwright | Buy |
| 2020-03-24 | Aggiornamento | Wedbush | Neutral → Outperform |
| 2020-03-04 | Iniziato | Barclays | Equal Weight |
| 2019-11-20 | Iniziato | Guggenheim | Buy |
| 2019-11-11 | Downgrade | Wedbush | Outperform → Neutral |
| 2019-06-13 | Iniziato | Mizuho | Buy |
| 2019-05-14 | Iniziato | Cantor Fitzgerald | Overweight |
| 2019-03-11 | Iniziato | Barclays | Overweight |
| 2018-11-26 | Iniziato | Piper Jaffray | Overweight |
| 2018-10-15 | Iniziato | Goldman | Neutral |
| 2018-09-13 | Iniziato | H.C. Wainwright | Buy |
| 2018-06-01 | Iniziato | SunTrust | Buy |
| 2018-01-05 | Iniziato | Citigroup | Buy |
| 2017-09-08 | Iniziato | Wedbush | Outperform |
| 2017-03-27 | Iniziato | H.C. Wainwright | Buy |
| 2017-03-02 | Iniziato | Instinet | Buy |
| 2017-01-03 | Downgrade | Oppenheimer | Outperform → Perform |
| 2015-11-02 | Iniziato | Oppenheimer | Outperform |
Mostra tutto
Cytomx Therapeutics Inc Borsa (CTMX) Ultime notizie
Jefferies reiterates Buy rating on CytomX stock after phase 1 data - Investing.com Canada
CytomX Therapeutics (NASDAQ:CTMX) Given New $12.00 Price Target at Piper Sandler - MarketBeat
CTMX: Piper Sandler Raises Price Target to $12 | CTMX Stock News - GuruFocus
Piper Sandler raises CytomX stock price target on drug trial data - Investing.com Canada
CytomX Therapeutics launches $250M public offering - MSN
Stock Market Today, March 16: CytomX Therapeutics Surges After Positive Phase 1 Colorectal Cancer Data - AOL.com
How Investors Are Reacting To CytomX Therapeutics (CTMX) Equity Raise And Encouraging Varseta-M Trial Data - Sahm
A Look At CytomX Therapeutics (CTMX) Valuation After Positive Varsetatug Masetecan Phase 1 Expansion Results - Yahoo Finance
Jefferies Raises CytomX Therapeutics (CTMX) Price Target to $16 - Insider Monkey
CytomX Therapeutics prices $250M public offering at $5.30 per share - MSN
CTMX Stock Pulls Back After 5-Year High: Share Sale Sparks Dilution Fears Despite Wall Street’s 150% Upside Calls - Stocktwits
Cytomx Therapeutics Insider Sold Shares Worth $764,138, According to a Recent SEC Filing - marketscreener.com
CTMX Stock Chart | CYTOMX THERAPEUTICS INC (NASDAQ:CTMX) - ChartMill
Yu-Waye Chu Sells 21,279 Shares of CytomX Therapeutics (NASDAQ:CTMX) Stock - MarketBeat
Sean Mccarthy Sells 118,969 Shares of CytomX Therapeutics (NASDAQ:CTMX) Stock - MarketBeat
Sean McCarthy, CytomX Therapeutics CEO, sells $764k in stock By Investing.com - Investing.com Canada
CytomX therapeutics (CTMX) chief medical officer sells $136k in stock - Investing.com Canada
CytomX Therapeutics (NASDAQ:CTMX) CFO Sells $124,053.66 in Stock - MarketBeat
Insider Selling: CytomX Therapeutics (NASDAQ:CTMX) SVP Sells 31,492 Shares of Stock - MarketBeat
CytomX (CTMX) CMO sells 21,279 shares to cover RSU tax obligations - Stock Titan
CytomX Therapeutics SVP Belvin sells $202k in stock By Investing.com - Investing.com Australia
Ogden, CytomX Therapeutics CFO, sells $124k in shares - Investing.com
CytomX Therapeutics SVP Belvin sells $202k in stock - Investing.com
CytomX Therapeutics (CTMX) CEO sells shares to cover RSU tax obligations - Stock Titan
Tax-driven share sale by CytomX (CTMX) chief scientist on RSU vesting - Stock Titan
CytomX Therapeutics (CTMX) reports Q4 loss, misses revenue estimates - MSN
CytomX (NASDAQ: CTMX) CFO sells 19,323 shares for tax withholding - Stock Titan
CytomX Therapeutics Raises $234 Million in Equity Offering - TipRanks
Why Is CytomX Therapeutics Stock Falling On Wednesday? - Sahm
CytomX prices $5.30 public offering to raise ~$234.4M; includes pre-funded warrants - TradingView
CytomX (NASDAQ: CTMX) prices $234.4M stock and pre-funded warrant deal - Stock Titan
CytomX Therapeutics (NASDAQ:CTMX) Given New $16.00 Price Target at Barclays - MarketBeat
CytomX Therapeutics (NASDAQ:CTMX) Shares Gap Up After Analyst Upgrade - MarketBeat
CTMX Sees Price Target Raised to $16 by Jefferies Today | CTMX S - GuruFocus
Jefferies Maintains Buy on CTMX (CytomX Therapeutics) March 18, 2026 - Meyka
Latham Watkins Advises CytomX Therapeutics on Offering of Common Stock Pre Funded Warrants - Latham & Watkins LLP
CytomX (NASDAQ: CTMX) offers 45.99M shares and 1.18M pre‑funded warrants - Stock Titan
CTMX Stock Garners Price Target Revisions After Colorectal Cancer Trial Data: Jefferies Sees As Much As 230% Upside - Stocktwits
Analysts bullish ahead of colorectal cancer readout for CytomX Therapeutics, Inc. (CTMX) - MSN
CytomX Stocks Slide Amidst Profit Woes and Revenue Shortfall - timothysykes.com
CytomX Therapeutics (CTMX) Gets Price Target Boost from Guggenhe - GuruFocus
CTMX: Key Managers in Recent Offering - GuruFocus
Barclays raises its price target on CytomX Therapeutics, Inc. (CTMX) to $10 and maintains an overweight rating - MSN
CytomX Therapeutics (NASDAQ:CTMX) Sees Strong Trading Volume Following Analyst Upgrade - MarketBeat
CytomX Therapeutics: Great News, But Early Data Do Not Quite Justify This Price Level - Seeking Alpha
CytomX Therapeutics (NASDAQ:CTMX) Price Target Raised to $15.00 at Guggenheim - MarketBeat
HC Wainwright Has Bearish Estimate for CTMX Q1 Earnings - MarketBeat
CytomX Therapeutics Prices $250 Million Securities Offering; Shares Up Pre-Bell - marketscreener.com
CytomX prices $250M stock offering at $5.30 per share By Investing.com - Investing.com South Africa
CytomX Therapeutics Inc receives Investment Bank Analyst Rating Update By Investing.com - Investing.com
CytomX Therapeutics Confronts Rising AI Regulatory Risks and Cost Pressures - The Globe and Mail
Cytomx Therapeutics Inc Azioni (CTMX) Dati Finanziari
Reddito
Reddito netto
Flusso di cassa
EPS
1.82%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):